IHAM
ZNTL icon

Integral Health Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Integral Health Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,050,000
Closed -$3.18M – 111
2024
Q4 		$3.18M Buy
+1,050,000
New +$3.44M 0.27% 72
2024
Q1 		– Sell
-250,000
Closed -$3.79M – 97
2023
Q4 		$3.79M Sell
250,000
-200,000
-44% -$2.92M 0.52% 62
2023
Q3 		$9.03M Hold
450,000
– – 1.25% 30
2023
Q2 		$12.7M Sell
450,000
-150,000
-25% -$3.6M 1.57% 21
2023
Q1 		$10.3M Sell
600,000
-150,000
-20% -$3.04M 2.08% 16
2022
Q4 		$15.1M Buy
750,000
+200,000
+36% +$4.3M 3.17% 8
2022
Q3 		$11.9M Buy
550,000
+209,757
+62% +$5.74M 2.31% 17
2022
Q2 		$9.56M Buy
340,243
+125,243
+58% +$3.32M 1.97% 17
2022
Q1 		$9.92M Buy
215,000
+95,000
+79% +$5.12M 2.58% 11
2021
Q4 		$10.1M Buy
120,000
+30,000
+33% +$2.32M 2.79% 10
2021
Q3 		$6M Sell
90,000
-35,000
-28% -$2.02M 1.72% 21
2021
Q2 		$6.65M Buy
125,000
+85,000
+213% +$4.55M 1.83% 20
2021
Q1 		$1.74M Buy
+40,000
New +$1.72M 0.5% 55

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's ZNTL Position: Q1 2025 in Review

Integral Health Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 1,050,000 shares — an estimated $3.18M sold.

Integral Health Asset Management first reported a position in ZNTL in Q1 2021 and held it in 13 quarters. The position peaked at $15.1M in Q4 2022. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Integral Health Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 1,050,000 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $3.18M.
  • Integral Health Asset Management first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Integral Health Asset Management's Zentalis Pharmaceuticals position peaked at $15.1M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.